188 related articles for article (PubMed ID: 37126606)
1. Real-world treatment patterns and healthcare resource utilization among migraine patients: a German claims database analysis.
Gaul C; Seidel K; Heuck A; Silaidos C; Mrosowsky T; Eberhardt A; Fritz B; Jacob C
J Med Econ; 2023; 26(1):667-678. PubMed ID: 37126606
[TBL] [Abstract][Full Text] [Related]
2. Direct cost and healthcare resource utilization of patients with migraine before treatment initiation with calcitonin gene-related peptide monoclonal antibodies by the number of prior preventive migraine medication classes.
Foster SA; Hoyt M; Ye W; Mason O; Ford JH
Curr Med Res Opin; 2022 May; 38(5):653-660. PubMed ID: 34761723
[TBL] [Abstract][Full Text] [Related]
3. Health care resource utilization and costs associated with treatment among patients initiating calcitonin gene-related peptide inhibitors vs other preventive migraine treatments in the United States.
Varnado OJ; Manjelievskaia J; Ye W; Perry A; Schuh K; Wenzel R
J Manag Care Spec Pharm; 2022 Aug; 28(8):818-829. PubMed ID: 35876297
[No Abstract] [Full Text] [Related]
4. Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.
Schwedt TJ; Lee J; Knievel K; McVige J; Wang W; Wu Z; Gillard P; Shah D; Blumenfeld AM
J Manag Care Spec Pharm; 2023 Oct; 29(10):1119-1128. PubMed ID: 37776119
[No Abstract] [Full Text] [Related]
5. The introduction of the CGRP monoclonal antibodies and their effect on the prescription patterns of chronic migraine preventive medications in a tertiary headache center: A retrospective, observational analysis.
Moskatel LS; Graber-Naidich A; He Z; Zhang N
Headache; 2024 Feb; 64(2):188-194. PubMed ID: 37882379
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
7. Patient characteristics and treatment utilization among patients with migraine initiating self-injectable calcitonin gene-related peptide monoclonal antibody and novel acute medication.
Varnado OJ; Hoyt M; Ye W; Nicholson R
Curr Med Res Opin; 2022 Aug; 38(8):1451-1457. PubMed ID: 35762152
[TBL] [Abstract][Full Text] [Related]
8. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
[TBL] [Abstract][Full Text] [Related]
9. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
[TBL] [Abstract][Full Text] [Related]
10. Treatment Patterns, Healthcare Resource Utilization, and Direct Costs Among Patients Initiating Concomitant Use of a Calcitonin Gene-Related Peptide Monoclonal Antibody (CGRP mAb) and Novel Acute Medication in the United States.
Varnado OJ; Gulati T; Wheeler A; Hoyt M
Patient Prefer Adherence; 2023; 17():3449-3459. PubMed ID: 38143945
[TBL] [Abstract][Full Text] [Related]
11. Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study.
Kawata AK; Shah N; Poon JL; Shaffer S; Sapra S; Wilcox TK; Shah S; Tepper SJ; Dodick DW; Lipton RB
Headache; 2021 Mar; 61(3):438-454. PubMed ID: 33594686
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience.
Raffaelli B; Fitzek M; Overeem LH; Storch E; Terhart M; Reuter U
J Headache Pain; 2023 Feb; 24(1):16. PubMed ID: 36843007
[TBL] [Abstract][Full Text] [Related]
13. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
[TBL] [Abstract][Full Text] [Related]
14. Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine.
Siersbæk N; Kilsdal L; Jervelund C; Antic S; Bendtsen L
BMC Neurol; 2023 Jul; 23(1):254. PubMed ID: 37400756
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic patterns and migraine disease burden in switchers of CGRP-targeted monoclonal antibodies - insights from the German NeuroTransData registry.
Hong JB; Israel-Willner H; Peikert A; Schanbacher P; Tozzi V; Köchling M; Reuter U; Raffaelli B;
J Headache Pain; 2024 Jun; 25(1):90. PubMed ID: 38825722
[TBL] [Abstract][Full Text] [Related]
16. Synergism of Anti-CGRP Monoclonal Antibodies and OnabotulinumtoxinA in the Treatment of Chronic Migraine: A Real-World Retrospective Chart Review.
Salim A; Hennessy E; Sonneborn C; Hogue O; Biswas S; Mays M; Suneja A; Ahmed Z; Mata IF
CNS Drugs; 2024 Jun; 38(6):481-491. PubMed ID: 38583127
[TBL] [Abstract][Full Text] [Related]
17. Patterns of anti-CGRP mAbs use and variation of triptan consumption following treatment initiation: A descriptive drug utilization study in the Tuscany region, Italy.
Hyeraci G; Paoletti O; Iannone LF; Gini R; De Cesaris F; Geppetti P; Roberto G
Headache; 2023; 63(10):1391-1402. PubMed ID: 37830925
[TBL] [Abstract][Full Text] [Related]
18. Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study.
Montisano DA; Giossi R; Canella M; Altamura C; Marcosano M; Vernieri F; Raggi A; Grazzi L
Toxins (Basel); 2024 Apr; 16(4):. PubMed ID: 38668603
[TBL] [Abstract][Full Text] [Related]
19. Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States.
McAllister P; Lamerato L; Krasenbaum LJ; Cohen JM; Tangirala K; Thompson S; Driessen M; Casciano J; Dotiwala Z; Mauskop A
J Headache Pain; 2021 Dec; 22(1):156. PubMed ID: 34930112
[TBL] [Abstract][Full Text] [Related]
20. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
